Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib and Alpelisib in PIK3CA-mutant HER2+ Metastatic Breast Cancer
NCT05230810Phase 2Active, not recruiting
- Sponsor
- Criterium
- Start
- Aug 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucatinib and alpelisib in breast cancer, sponsored by Criterium. Primary endpoints: Phase Ib Safety and Tolerability (Adverse Events and Serious Adverse Events) at 10 months and Progression-Free Survival at 20 months. Started Aug 2022; status: active, not recruiting.
02
Drugs
tucatinibalpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05230810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05230810.